MCID: DRG001
MIFTS: 38

Drug Psychosis malady

Categories: Mental diseases

Aliases & Classifications for Drug Psychosis

Aliases & Descriptions for Drug Psychosis:

Name: Drug Psychosis 12 14
Drug-Induced Psychotic Disorder 12
Psychoses, Substance-Induced 42
Drug-Induced Psychosis 12
Psychoses, Drug 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1742
ICD9CM 35 292.1
MeSH 42 D011605
UMLS 69 C0033937

Summaries for Drug Psychosis

MalaCards based summary : Drug Psychosis, also known as drug-induced psychotic disorder, is related to schizophrenia and polyneuropathy. An important gene associated with Drug Psychosis is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Serotonergic synapse and GPCRs, Other. The drugs Aripiprazole and Asenapine have been mentioned in the context of this disorder. Related phenotypes are shRNA abundance <= 50% and behavior/neurological

Related Diseases for Drug Psychosis

Diseases related to Drug Psychosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 28.8 CNR1 DRD2 HTR1A HTR2A HTR7 NDUFS4
2 polyneuropathy 10.3 HTR1A HTR2A
3 antisocial personality disorder 10.3 HTR1A HTR2A
4 aryepiglottic fold cancer 10.3 HTR1A HTR2A
5 optic disk drusen 10.2 IDH1 IDH2
6 waardenburg's syndrome 10.2 DRD2 HTR1A HTR2A
7 enterovesical fistula 10.2 IDH1 IDH2
8 acrocallosal syndrome 10.2 IDH1 IDH2
9 postencephalitic parkinson disease 10.2 DRD2 HTR1A HTR2A
10 neurilemmoma 10.2 IDH1 IDH2
11 cecal benign neoplasm 10.1 DRD2 HTR1A HTR2A
12 testis refractory cancer 10.1 IDH1 IDH2
13 cytomegalic congenital adrenal hypoplasia 10.1 DRD2 HTR2A NDUFS4
14 cystinosis, nephropathic 10.1 IDH1 IDH2
15 small cell osteogenic sarcoma 10.1 IDH1 IDH2
16 hepatitis d 10.1 DRD2 HTR1A HTR2A
17 hereditary multiple exostoses 10.1 CNR1 DRD2 HTR2A
18 abnormal pupillary function 10.1 HTR1A HTR7
19 dry eye syndrome 10.1 HTR1A HTR2A HTR7
20 glycogen storage disease type 0 10.1 IDH1 IDH2
21 keratosis 10.1 HTR1A HTR2A HTR7
22 alzheimer disease 17 10.1 HTR1A HTR2A HTR7
23 angioma hereditary neurocutaneous 10.1 IDH1 IDH2
24 retinoblastoma 10.1 DRD2 HTR1A HTR2A
25 neuropathy, ataxia, and retinitis pigmentosa 10.1 IDH1 IDH2
26 chronic conjunctivitis 10.1 CNR1 DRD2 HTR1A HTR2A
27 benign epilepsy with centrotemporal spikes 10.1 CNR1 DRD2 HTR1A HTR2A
28 breast papillomatosis 10.0 IDH1 IDH2
29 prosopagnosia 10.0 IDH1 IDH2
30 indeterminate leprosy 10.0 HTR2A HTR7
31 rectosigmoid junction neoplasm 10.0 CNR1 DRD2 HTR7
32 hemochromatosis, type 2a 9.9 DRD2 NDUFS4 PINK1
33 microcephaly 13, primary, autosomal recessive 9.9 DRD2 HTR1A HTR2A HTR7
34 spinal cord astrocytoma 9.9 IDH1 IDH2
35 mixed lacrimal gland cancer 9.9 FOS HTR1A HTR7
36 autoimmune disease of endocrine system 9.8 CNR1 FOS HTR7
37 cervical carcinosarcoma 9.8 CNR1 FOS HTR7
38 preeclampsia/eclampsia 5 9.8 CNR1 DRD2 HTR1A HTR2A HTR7
39 ellis-van creveld syndrome 9.8 DRD2 FOS HTR1A HTR2A
40 siberian tick typhus 9.8 CNR1 FOS HTR1A HTR7
41 koro 9.7
42 capgras syndrome 9.7
43 personality disorder 9.4 ADAMTS2 CNR1 DRD2 FOS HTR1A HTR2A
44 allergic hypersensitivity disease 8.1 ADAMTS2 CNR1 DRD2 DUSP26 EPHA5 FOS
45 vascular cancer 8.1 ADAMTS2 CNR1 DRD2 DUSP26 EPHA5 FOS

Graphical network of the top 20 diseases related to Drug Psychosis:



Diseases related to Drug Psychosis

Symptoms & Phenotypes for Drug Psychosis

GenomeRNAi Phenotypes related to Drug Psychosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ADAMTS2 DRD2 DUSP26 EPHA5 FOS HTR1A

MGI Mouse Phenotypes related to Drug Psychosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CNR1 DRD2 FOS HTR1A HTR2A HTR7
2 growth/size/body region MP:0005378 9.96 CNR1 DRD2 DUSP26 FOS IDH1 NDUFS4
3 integument MP:0010771 9.7 ADAMTS2 CNR1 DRD2 FOS HTR7 NDUFS4
4 nervous system MP:0003631 9.61 HTR1A HTR7 NDUFS4 PINK1 TCOF1 CNR1
5 skeleton MP:0005390 9.32 ADAMTS2 CNR1 DRD2 FOS HTR2A IDH1

Drugs & Therapeutics for Drug Psychosis

Drugs for Drug Psychosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 987)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
5
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
6
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
7
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
8
Coal tar Approved Phase 4,Phase 2 8007-45-2
9
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
10
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
11
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
12
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
13
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
14
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
15
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
16
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1 5786-21-0 2818
17 Moxonidine Approved Phase 4 75438-57-2 4810
18
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 28981-97-7 2118
19
Zolpidem Approved Phase 4,Phase 3,Phase 2,Phase 1 82626-48-0 5732
20 Zotepine Approved Phase 4 26615-21-4
21
Sulpiride Approved Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
22
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 93-14-1 3516
23
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 76-99-3 4095
24
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
25
Chlorpromazine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
26
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
27
Guanfacine Approved, Investigational Phase 4,Phase 2,Phase 1 29110-47-2 3519
28
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
29
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
30
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-41-2 439260
31
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
32
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 2078-54-8 4943
33
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206
34
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
35
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
36
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1 34841-39-9, 34911-55-2 444
37
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
38
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
39
Mianserin Approved Phase 4,Phase 3,Phase 2 24219-97-4 4184
40
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-52-8, 61337-67-5 4205
41
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
42
Nortriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1 72-69-5 4543
43
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
44
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
45
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 79617-96-2 68617
46
Trimipramine Approved Phase 4,Phase 3 739-71-9 5584 4055
47
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Early Phase 1 148553-50-8 5486971
48
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
49
Clobazam Approved, Illicit Phase 4,Phase 3 22316-47-8 2789
50
Clonazepam Approved, Illicit Phase 4,Phase 2,Phase 3 1622-61-3 2802

Interventional clinical trials:

(show top 50) (show all 5005)
id Name Status NCT ID Phase
1 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
2 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4
3 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4
4 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
5 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4
6 Ziprasidone vs Standard Therapy for Agitated Patients in the ED Unknown status NCT00786318 Phase 4
7 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4
8 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4
9 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
10 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
11 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4
12 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
13 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4
14 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
15 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4
16 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4
17 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
18 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4
19 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4
20 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4
21 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4
22 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
23 Attention Deficit Disorder Medication Response Study Unknown status NCT01727414 Phase 4
24 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4
25 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4
26 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4
27 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4
28 Long Term Postoperative Cognitive Dysfunction in the Elderly Patients Unknown status NCT02301676 Phase 4
29 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4
30 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
31 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4
32 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4
33 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers Unknown status NCT01714323 Phase 4
34 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4
35 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4
36 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4
37 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4
38 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4
39 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4
40 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4
41 Divalproex Sodium ER in Adult Autism Unknown status NCT00211796 Phase 4
42 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4
43 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4
44 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4
45 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4
46 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4
47 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4
48 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
49 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4
50 Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure Unknown status NCT00633685 Phase 4

Search NIH Clinical Center for Drug Psychosis

Cochrane evidence based reviews: psychoses, substance-induced

Genetic Tests for Drug Psychosis

Anatomical Context for Drug Psychosis

Publications for Drug Psychosis

Articles related to Drug Psychosis:

id Title Authors Year
1
Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. ( 11812256 )
2002

Variations for Drug Psychosis

Expression for Drug Psychosis

Search GEO for disease gene expression data for Drug Psychosis.

Pathways for Drug Psychosis

GO Terms for Drug Psychosis

Cellular components related to Drug Psychosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 CNR1 DRD2 EPHA5 HTR2A PINK1

Biological processes related to Drug Psychosis according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.99 CNR1 DRD2 HTR1A HTR2A HTR7 LHB
2 mitochondrion organization GO:0007005 9.65 IDH2 PHB2 PINK1
3 response to light stimulus GO:0009416 9.59 DRD2 FOS
4 regulation of dopamine secretion GO:0014059 9.58 DRD2 HTR2A
5 temperature homeostasis GO:0001659 9.58 DRD2 HTR2A
6 behavioral response to cocaine GO:0048148 9.57 DRD2 HTR2A
7 smooth muscle contraction GO:0006939 9.56 HTR2A HTR7
8 2-oxoglutarate metabolic process GO:0006103 9.55 IDH1 IDH2
9 vasoconstriction GO:0042310 9.54 HTR1A HTR7
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.52 DRD2 HTR2A
11 regulation of synaptic transmission, GABAergic GO:0032228 9.49 CNR1 DRD2
12 sleep GO:0030431 9.46 FOS HTR2A
13 behavior GO:0007610 9.43 HTR1A HTR2A
14 regulation of behavior GO:0050795 9.4 HTR1A HTR2A
15 serotonin receptor signaling pathway GO:0007210 9.37 HTR1A HTR2A
16 regulation of hormone secretion GO:0046883 9.32 HTR1A HTR2A
17 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
18 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.16 HTR1A HTR7
19 negative regulation of dopamine secretion GO:0033602 8.96 CNR1 DRD2
20 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Drug Psychosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.71 CNR1 DRD2 HTR1A HTR2A
2 drug binding GO:0008144 9.54 CNR1 DRD2 HTR2A
3 G-protein coupled serotonin receptor activity GO:0004993 9.5 HTR1A HTR2A HTR7
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
6 neurotransmitter receptor activity GO:0030594 9.13 HTR1A HTR2A HTR7
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR7

Sources for Drug Psychosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....